文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

左西孟旦促进严重心源性休克患者脱离ECMO:LEVOECMO随机临床试验

Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

在法国11个ICU开展的双盲安慰剂对照试验中,205例接受VA-ECMO的急性心源性休克患者随机接受早期左西孟旦或安慰剂。30天内成功脱离ECMO的比例两组均为68.3%,风险差0.0%(95%CI -12.8%至12.7%),亚分布风险比1.02(95%CI 0.74-1.39;P=0.92),无显著差异。左西孟旦组室性心律失常发生率更高(17.8% vs 8.7%)。

要点

  • 早期左西孟旦未显著缩短VA-ECMO成功脱离时间(亚分布风险比1.02,P=0.92)。
  • 30天成功脱离ECMO比例左西孟旦组与安慰剂组均为68.3%。
  • 左西孟旦组室性心律失常发生率17.8%,高于安慰剂组的8.7%。

核心结论

  • 在严重但可能可逆的心源性休克并接受VA-ECMO支持的患者中,与安慰剂相比,早期给予左西孟旦未显著缩短成功脱离ECMO的时间。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在法国11个重症监护病房(ICU)开展。
  • 2021年8月27日至2024年9月10日期间纳入205例在前48小时内开始VA-ECMO的成人急性心源性休克患者,最终随访于2024年11月10日完成。
  • 患者按1:1随机接受左西孟旦0.15 μg/kg/min、2小时后增至0.20 μg/kg/min(n=101)或安慰剂(n=104)。

主要发现

  • 205例随机患者中位年龄58岁(IQR 50-67),男性149例(72.7%);主要病因包括心脏术后79例(38.5%)、急性心肌梗死56例(27.3%)、心肌炎28例(13.7%)。
  • 30天内成功脱离ECMO:左西孟旦组69/101例(68.3%)vs 安慰剂组71/104例(68.3%),风险差0.0%(95%CI -12.8%至12.7%),亚分布风险比1.02(95%CI 0.74-1.39;P=0.92)。
  • 中位ECMO持续时间:左西孟旦组5天(IQR 4-7)vs 安慰剂组6天(IQR 4-11)(P=0.53);平均ICU住院时间:左西孟旦组18天(SD 15)vs 安慰剂组19天(SD 15)(P=0.42),均无显著差异。
  • 60天死亡率:左西孟旦组27.7% vs 安慰剂组25.0%,风险差2.7%(95%CI -9.0%至15.3%;P=0.78),无显著差异。
  • 室性心律失常:左西孟旦组18例(17.8%)vs 安慰剂组9例(8.7%),绝对风险差9.2%(95%CI 0.4%-18.1%)。

关键数值与推荐

  • 主要结局为随机化后30天内成功脱离ECMO的时间。
  • 次要结局包括无ECMO、无机械通气、无器官衰竭天数,ICU和住院时间,严重不良事件,以及30天和60天全因死亡率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited. OBJECTIVE: To assess whether early administration of levosimendan reduces the time to successful VA-ECMO weaning in patients with severe but potentially reversible cardiogenic shock. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted across 11 intensive care units (ICUs) in France. Between August 27, 2021, and September 10, 2024, 205 adult patients with acute cardiogenic shock who had started VA-ECMO in the preceding 48 hours were enrolled. Final follow-up was completed on November 10, 2024. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive levosimendan, 0.15 μg/kg per minute, to be increased to 0.20 μg/kg per minute after 2 hours (n = 101), or placebo (n = 104). MAIN OUTCOMES AND MEASURES: The primary outcome was time to successful ECMO weaning within 30 days following randomization. Secondary outcomes included ECMO-, mechanical ventilation-, and organ failure-free days, ICU and hospital lengths of stay, serious adverse events, and all-cause 30- and 60-day mortality. RESULTS: Among the 205 randomized patients (median age, 58 [IQR, 50-67] years; 149 [72.7%] male), main cardiogenic shock etiologies were postcardiotomy (79 [38.5%]), acute myocardial infarction (56 [27.3%]), and myocarditis (28 [13.7%]). Treatment dose was increased to 0.20 ± 0.01 μg/kg per minute in 93% of patients receiving levosimendan and in 96% of those receiving placebo. Within 30 days, 69 of 101 patients (68.3%) had a successful ECMO weaning in the levosimendan group compared with 71 of 104 (68.3%) in the placebo group (risk difference, 0.0% [95% CI, -12.8% to 12.7%]; subdistribution hazard ratio, 1.02 [95% CI, 0.74-1.39]; P = .92). In the levosimendan and placebo groups, respectively, median ECMO duration (5 [IQR, 4-7] days vs 6 [IQR, 4-11] days; P = .53), mean ICU length of stay (18 [SD, 15] days vs 19 [SD, 15] days; P = .42), and 60-day mortality (27.7% vs 25.0%; risk difference, 2.7% [95% CI, -9.0% to 15.3%]; P = .78) did not differ significantly. Ventricular arrhythmias occurred more frequently with levosimendan (18 [17.8%] vs 9 [8.7%]; absolute risk difference, 9.2% [95% CI, 0.4%-18.1%]). CONCLUSIONS AND RELEVANCE: Among patients with severe but potentially reversible cardiogenic shock supported by VA-ECMO, early levosimendan administration did not significantly reduce the time to successful weaning of ECMO compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04728932.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Combes A, Saura O, Nesseler N, et al. Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial. JAMA. 2026. PMID: 41324946. doi:10.1001/jama.2025.19843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。